Praxis Precision Medicines Stock Performance
| PRAX Stock | USD 74.68 0.18 0.24% |
On a scale of 0 to 100, Praxis Precision holds a performance score of 11. The company holds a Beta of 1.16, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Praxis Precision will likely underperform. Please check Praxis Precision's potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether Praxis Precision's historical price patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Praxis Precision Medicines are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Praxis Precision showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.05 | Five Day Return 3.71 | Year To Date Return 260.19 | Ten Year Return (81.95) | All Time Return (81.95) |
Last Split Factor 1:15 | Last Split Date 2023-11-29 |
1 | Were Hopeful That Praxis Precision Medicines Will Use Its Cash Wisely | 08/30/2024 |
2 | Acquisition by Nemiroff Alex of 7500 shares of Praxis Precision at 1.63 subject to Rule 16b-3 | 09/20/2024 |
3 | Praxis Precision Medicines Moves 8.4 percent Higher Will This Strength Last | 10/04/2024 |
4 | Disposition of 3057 shares by Ravina Bernard of Praxis Precision at 12.85 subject to Rule 16b-3 | 10/17/2024 |
5 | Were Not Very Worried About Praxis Precision Medicines Cash Burn Rate | 10/21/2024 |
6 | Vanguard Group Incs Strategic Acquisition in Praxis Precision Medicines Inc | 11/05/2024 |
7 | Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results | 11/06/2024 |
8 | Praxis Precision Medicines Inc Q3 2024 Earnings Call Highlights Strong Cash Position ... | 11/07/2024 |
9 | Piper Sandler maintains stock target on PRAX, confident in ET drug | 11/12/2024 |
10 | Disposition of 5188 shares by Lauren Mastrocola of Praxis Precision at 81.783 subject to Rule 16b-3 | 11/14/2024 |
11 | RA Capital Management Reduces Stake in Praxis Precision Medicines Inc | 11/15/2024 |
12 | Praxis Precision Medicines Shares Gap Down After Insider Selling - MarketBeat | 11/18/2024 |
| Begin Period Cash Flow | 62 M |
Praxis |
Praxis Precision Relative Risk vs. Return Landscape
If you would invest 5,352 in Praxis Precision Medicines on August 27, 2024 and sell it today you would earn a total of 2,098 from holding Praxis Precision Medicines or generate 39.2% return on investment over 90 days. Praxis Precision Medicines is currently generating 0.5924% in daily expected returns and assumes 3.9052% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Praxis, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Praxis Precision Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Praxis Precision's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Praxis Precision Medicines, and traders can use it to determine the average amount a Praxis Precision's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1517
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PRAX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.91 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.59 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Praxis Precision is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Praxis Precision by adding it to a well-diversified portfolio.
Praxis Precision Fundamentals Growth
Praxis Stock prices reflect investors' perceptions of the future prospects and financial health of Praxis Precision, and Praxis Precision fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Praxis Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (188.20) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 18.64 M | ||||
| Price To Book | 3.63 X | ||||
| Price To Sales | 865.12 X | ||||
| Revenue | 2.45 M | ||||
| EBITDA | (125.94 M) | ||||
| Net Income | (123.28 M) | ||||
| Cash And Equivalents | 165.4 M | ||||
| Cash Per Share | 3.70 X | ||||
| Total Debt | 2.5 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 4.56 X | ||||
| Book Value Per Share | 21.52 X | ||||
| Cash Flow From Operations | (111.14 M) | ||||
| Earnings Per Share | (9.17) X | ||||
| Market Capitalization | 1.39 B | ||||
| Total Asset | 87.95 M | ||||
| Retained Earnings | (653.92 M) | ||||
| Working Capital | 69.13 M | ||||
About Praxis Precision Performance
Evaluating Praxis Precision's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Praxis Precision has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Praxis Precision has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (1.75) | (1.84) | |
| Return On Assets | (1.40) | (1.47) | |
| Return On Equity | (1.77) | (1.86) |
Things to note about Praxis Precision Med performance evaluation
Checking the ongoing alerts about Praxis Precision for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Praxis Precision Med help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Praxis Precision Med appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 2.45 M. Net Loss for the year was (123.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Praxis Precision Medicines currently holds about 165.4 M in cash with (111.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7. | |
| Praxis Precision Med has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Praxis Precision Medicines Shares Gap Down After Insider Selling - MarketBeat |
- Analyzing Praxis Precision's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Praxis Precision's stock is overvalued or undervalued compared to its peers.
- Examining Praxis Precision's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Praxis Precision's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Praxis Precision's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Praxis Precision's stock. These opinions can provide insight into Praxis Precision's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Praxis Stock Analysis
When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.